Reunion Neuroscience Performance

The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Reunion Neuroscience are completely uncorrelated.

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Reunion Neuroscience has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Reunion Neuroscience is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Begin Period Cash Flow64.5 M
Free Cash Flow-28.2 M
  

Reunion Neuroscience Relative Risk vs. Return Landscape

If you would invest (100.00) in Reunion Neuroscience on December 8, 2024 and sell it today you would earn a total of  100.00  from holding Reunion Neuroscience or generate -100.0% return on investment over 90 days. Reunion Neuroscience is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Reunion, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
JavaScript chart by amCharts 3.21.15CashMarketREUN 0.00.10.20.30.40.50.60.70.8 -0.06-0.05-0.04-0.03-0.02-0.010.000.01
       Risk  

Reunion Neuroscience Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Reunion Neuroscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Reunion Neuroscience, and traders can use it to determine the average amount a Reunion Neuroscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
REUN
Based on monthly moving average Reunion Neuroscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Reunion Neuroscience by adding Reunion Neuroscience to a well-diversified portfolio.

Reunion Neuroscience Fundamentals Growth

Reunion Stock prices reflect investors' perceptions of the future prospects and financial health of Reunion Neuroscience, and Reunion Neuroscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Reunion Stock performance.

Things to note about Reunion Neuroscience performance evaluation

Checking the ongoing alerts about Reunion Neuroscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Reunion Neuroscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Reunion Neuroscience is not yet fully synchronised with the market data
Reunion Neuroscience has some characteristics of a very speculative penny stock
Reunion Neuroscience has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (48.49 M) with loss before overhead, payroll, taxes, and interest of (4.29 M).
Reunion Neuroscience currently holds about 48.13 M in cash with (27.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.14.
Roughly 34.0% of the company outstanding shares are owned by corporate insiders
Evaluating Reunion Neuroscience's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Reunion Neuroscience's stock performance include:
  • Analyzing Reunion Neuroscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Reunion Neuroscience's stock is overvalued or undervalued compared to its peers.
  • Examining Reunion Neuroscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Reunion Neuroscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Reunion Neuroscience's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Reunion Neuroscience's stock. These opinions can provide insight into Reunion Neuroscience's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Reunion Neuroscience's stock performance is not an exact science, and many factors can impact Reunion Neuroscience's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Consideration for investing in Reunion Stock

If you are still planning to invest in Reunion Neuroscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reunion Neuroscience's history and understand the potential risks before investing.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Commodity Directory
Find actively traded commodities issued by global exchanges
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments